management of hepatorenal syndrome in short

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Reading File

Finding Sources

Searching PubMed

"hepatorenal syndrome" AND treatment

Reading File

Management of Hepatorenal Syndrome (HRS) - Short Summary

1. Confirm diagnosis (exclusion criteria first)

Cirrhosis with ascites + rise in creatinine (AKI: ≥0.3 mg/dL rise in 48h or ≥50% from baseline)
Stop diuretics and any nephrotoxic drugs (NSAIDs, aminoglycosides)
Rule out other causes of AKI: volume depletion (GI bleed, overdiuresis, diarrhea from lactulose), sepsis/SBP, intrinsic renal disease (ATN, glomerulonephritis, interstitial nephritis), obstruction
Give albumin challenge: 1 g/kg/day IV for 2 days (max ~100 g/day) - no improvement in creatinine confirms HRS-AKI (formerly Type 1 HRS)

2. Medical (pharmacologic) therapy

First line: Terlipressin + albumin (splanchnic vasoconstrictor) - most effective agent, improves renal function and reverses HRS in a significant proportion of patients (confirmed by recent meta-analyses)
If terlipressin unavailable: Norepinephrine + albumin (requires ICU monitoring) - similar efficacy
Third-line (US, when above unavailable): Midodrine (oral alpha-agonist) + octreotide + IV albumin - less effective than terlipressin/norepinephrine
Continue albumin infusion alongside vasoconstrictor to maintain effective volume

3. Treat underlying precipitant

Antibiotics if SBP present
Correct GI bleeding, stop overdiuresis, treat diarrhea

4. If pharmacologic therapy fails

Renal replacement therapy (dialysis/CRRT) as a bridge, mainly for patients awaiting transplant or with reversible liver disease
TIPS (transjugular intrahepatic portosystemic shunt) may be considered in select patients without contraindications (encephalopathy risk) - Cochrane review supports possible benefit but evidence is limited

5. Definitive treatment

Liver transplantation is the only curative therapy - renal function typically recovers post-transplant
Combined liver-kidney transplant considered if renal failure has been prolonged (>4-6 weeks) or with structural kidney damage

Prognosis: Poor without transplant; HRS-AKI (rapidly progressive) carries worse short-term prognosis than HRS-CKD (stable, chronic form).

Sources: Harrison's Principles of Internal Medicine, 22nd ed.; Goldman-Cecil Medicine, International Edition.

Recent evidence note: A 2025 meta-analysis (PMID: 40207491) and a 2024 systematic review (PMID: 39295934) both confirm terlipressin + albumin as effective first-line therapy for HRS reversal compared to placebo/noradrenaline, consistent with the textbook guidance above. A 2024 Cochrane review (PMID: 38235907) on TIPS for HRS found the evidence base still limited/low-certainty, so this remains a secondary option rather than routine practice.

Create a clinical decision flowchart or summary document for HRS management

Browsing Directory

/tmp/workspace

Reading File

Running Command

mkdir -p /tmp/workspace/hrs-management/output && ls -la /tmp/workspace/hrs-management

Writing File

~/hrs-management/build_flowchart.py

import matplotlib
matplotlib.use("Agg")
import matplotlib.pyplot as plt
from matplotlib.patches import FancyBboxPatch, FancyArrowPatch
from matplotlib.lines import Line2D

fig, ax = plt.subplots(figsize=(11, 16))
ax.set_xlim(0, 10)
ax.set_ylim(0, 100)
ax.axis("off")

def box(x, y, w, h, text, fc="#eaf2fb", ec="#2c5f8a", fontsize=9.5, weight="normal"):
    b = FancyBboxPatch((x, y), w, h, boxstyle="round,pad=0.15,rounding_size=0.3",
                        linewidth=1.4, edgecolor=ec, facecolor=fc)
    ax.add_patch(b)
    ax.text(x + w/2, y + h/2, text, ha="center", va="center", fontsize=fontsize,
             weight=weight, wrap=True, linespacing=1.35)
    return (x + w/2, y, x + w/2, y + h)

def arrow(x1, y1, x2, y2, text=None, color="#333333"):
    a = FancyArrowPatch((x1, y1), (x2, y2), arrowstyle="-|>", mutation_scale=14,
                         linewidth=1.3, color=color)
    ax.add_patch(a)
    if text:
        ax.text((x1 + x2)/2 + 0.15, (y1 + y2)/2, text, fontsize=8.5, color=color,
                 ha="left", va="center", style="italic")

# Title
ax.text(5, 98.5, "Hepatorenal Syndrome (HRS) - Management Algorithm", ha="center",
        va="center", fontsize=15, weight="bold", color="#1a3a5c")

# Box 1: Trigger
cx, by, cx2, ty = box(1.3, 92, 7.4, 4.3,
    "Cirrhosis / advanced liver disease with ascites\n+ Acute Kidney Injury\n(Cr rise \u22650.3 mg/dL in 48h OR \u226550% from baseline)",
    fc="#fde9d9", ec="#b5651d", weight="bold")

# Box 2: Step 1
box2 = box(1.3, 85.5, 7.4, 4.8,
    "STEP 1 - Immediate actions\n\u2022 Stop diuretics & nephrotoxic drugs (NSAIDs, aminoglycosides)\n\u2022 Stop any vasodilators\n\u2022 Send urinalysis, urine sediment, renal ultrasound")
arrow(5, 92, 5, 90.3)

# Box 3: Step 2 exclude other causes
box3 = box(1.3, 78.5, 7.4, 5.5,
    "STEP 2 - Exclude other causes of AKI\n\u2022 Volume depletion (GI bleed, over-diuresis, lactulose-induced diarrhea) \u2192 correct with fluids\n\u2022 Sepsis / SBP \u2192 diagnostic paracentesis, treat infection\n\u2022 Obstruction, ATN, interstitial nephritis, glomerulonephritis \u2192 evaluate & exclude")
arrow(5, 85.5, 5, 84.0)

# Box 4: albumin challenge
box4 = box(1.3, 71.5, 7.4, 5.0,
    "STEP 3 - Plasma volume expansion (albumin challenge)\nIV Albumin 1 g/kg/day (max ~100 g/day) x 48 hours",
    fc="#eaf2fb", weight="bold")
arrow(5, 78.5, 5, 76.5)

# Branch point
ax.text(5, 69.8, "Reassess serum creatinine after albumin challenge", ha="center",
        fontsize=9, style="italic", color="#444444")

# Left branch: improves
boxL = box(0.3, 61.5, 4.0, 5.5,
    "Creatinine IMPROVES\n\u2192 NOT HRS\nTreat underlying cause\n(e.g. hypovolemia, ATN, sepsis)",
    fc="#e3f2e1", ec="#3a7d34")
arrow(3.5, 71.5, 2.3, 67.0, text="Improves")

# Right branch: no improvement -> HRS diagnosis
boxR = box(5.7, 61.5, 4.0, 5.5,
    "NO improvement\n\u2192 Diagnosis: HRS-AKI\n(rapid, Type 1) or\nHRS-CKD (stable, Type 2)",
    fc="#fbe3e3", ec="#a33a3a", weight="bold")
arrow(6.5, 71.5, 7.7, 67.0, text="No response")

# Box 5: pharmacologic therapy
box5 = box(1.3, 53.0, 7.4, 6.5,
    "STEP 4 - Pharmacologic therapy (ICU / monitored setting) + continue albumin\n\n1st line: Terlipressin + Albumin\n2nd line (if terlipressin unavailable): Norepinephrine + Albumin\n3rd line (US, limited access): Midodrine (oral \u03b1-agonist) + Octreotide + Albumin",
    fc="#eaf2fb", ec="#2c5f8a", weight="bold")
arrow(7.7, 61.5, 6.7, 59.5)

# Box 6: reassess
box6 = box(1.3, 46.0, 7.4, 4.8,
    "Reassess renal function at 48-72 hours\n(repeat serum creatinine, urine output)")
arrow(5, 53.0, 5, 50.8)

# Left branch: response
boxL2 = box(0.3, 37.5, 4.0, 5.5,
    "RESPONSE\n(Cr trending down)\n\u2192 Continue vasoconstrictor\n+ albumin up to 14 days,\nthen taper",
    fc="#e3f2e1", ec="#3a7d34")
arrow(3.5, 46.0, 2.3, 43.0, text="Responds")

boxR2 = box(5.7, 37.5, 4.0, 5.5,
    "NO RESPONSE /\nREFRACTORY HRS\n\u2192 Proceed to Step 5",
    fc="#fbe3e3", ec="#a33a3a", weight="bold")
arrow(6.5, 46.0, 7.7, 43.0, text="No response")

# Box 7: refractory options
box7 = box(1.3, 28.5, 7.4, 6.5,
    "STEP 5 - Refractory HRS: options\n\u2022 Renal replacement therapy (dialysis/CRRT) - bridge therapy\n\u2022 TIPS - selected patients without contraindications (e.g. encephalopathy) - evidence limited\n\u2022 Urgent liver transplant evaluation",
    fc="#fdf3d0", ec="#a5871a", weight="bold")
arrow(7.7, 37.5, 6.7, 35.0)

# Box 8: transplant - definitive
box8 = box(1.3, 20.5, 7.4, 5.5,
    "DEFINITIVE TREATMENT: Liver Transplantation\nRenal function typically recovers post-transplant.\nConsider combined liver-kidney transplant if renal\nfailure prolonged (>4-6 weeks) or structural kidney damage.",
    fc="#d9ecfb", ec="#1a5c8a", weight="bold")
arrow(5, 28.5, 5, 26.0)

# Prognosis note
box9 = box(1.3, 14.5, 7.4, 4.5,
    "Prognosis: Poor without transplant.\nHRS-AKI (rapid) has worse short-term prognosis than\nHRS-CKD (stable, chronic).",
    fc="#f2f2f2", ec="#666666", fontsize=9)
arrow(5, 20.5, 5, 19.0)

# Footer / sources
ax.text(5, 11.5, "Sources: Harrison's Principles of Internal Medicine, 22nd ed.; Goldman-Cecil Medicine, Intl. Ed.\n"
                 "Recent evidence: PMID 40207491 (2025 meta-analysis), PMID 39295934 (2024 systematic review),\n"
                 "PMID 38235907 (2024 Cochrane review on TIPS)",
        ha="center", fontsize=7.5, color="#555555", style="italic")

plt.tight_layout()
plt.savefig("/tmp/workspace/hrs-management/output/hrs_flowchart.png", dpi=200, bbox_inches="tight")
print("Flowchart saved.")

Running Command

cd /tmp/workspace/hrs-management && python3 build_flowchart.py

Writing File

~/hrs-management/build_docx.py

from docx import Document
from docx.shared import Pt, Inches, RGBColor
from docx.enum.text import WD_ALIGN_PARAGRAPH
from docx.enum.table import WD_TABLE_ALIGNMENT
from docx.oxml.ns import qn
from docx.oxml import OxmlElement

doc = Document()

style = doc.styles["Normal"]
style.font.name = "Calibri"
style.font.size = Pt(11)

def set_cell_shading(cell, color_hex):
    tcPr = cell._tc.get_or_add_tcPr()
    shd = OxmlElement('w:shd')
    shd.set(qn('w:val'), 'clear')
    shd.set(qn('w:color'), 'auto')
    shd.set(qn('w:fill'), color_hex)
    tcPr.append(shd)

def add_table(headers, rows, col_widths=None):
    table = doc.add_table(rows=1, cols=len(headers))
    table.style = "Light Grid Accent 1"
    table.alignment = WD_TABLE_ALIGNMENT.CENTER
    hdr_cells = table.rows[0].cells
    for i, h in enumerate(headers):
        hdr_cells[i].text = h
        for p in hdr_cells[i].paragraphs:
            for r in p.runs:
                r.font.bold = True
                r.font.color.rgb = RGBColor(0xFF, 0xFF, 0xFF)
        set_cell_shading(hdr_cells[i], "1F4E79")
    for row in rows:
        cells = table.add_row().cells
        for i, val in enumerate(row):
            cells[i].text = str(val)
    return table

# Title
title = doc.add_heading("Hepatorenal Syndrome (HRS): Clinical Management Summary", level=0)
for r in title.runs:
    r.font.color.rgb = RGBColor(0x1A, 0x3A, 0x5C)

sub = doc.add_paragraph()
sub_run = sub.add_run("Quick-reference decision summary for inpatient management of HRS in cirrhosis / advanced liver disease")
sub_run.italic = True
sub_run.font.size = Pt(11)
sub_run.font.color.rgb = RGBColor(0x55, 0x55, 0x55)

doc.add_paragraph()

# Overview
doc.add_heading("Overview", level=1)
doc.add_paragraph(
    "Hepatorenal syndrome (HRS) is a form of functional renal failure without intrinsic renal "
    "pathology, occurring in advanced cirrhosis or acute liver failure due to marked splanchnic "
    "arterial vasodilation with compensatory renal vasoconstriction. It is a diagnosis of "
    "exclusion made after other causes of acute kidney injury (AKI) have been ruled out and "
    "renal function fails to improve with volume expansion (albumin)."
)

# Flowchart image
doc.add_heading("Decision Flowchart", level=1)
doc.add_picture("/tmp/workspace/hrs-management/output/hrs_flowchart.png", width=Inches(6.3))
last_par = doc.paragraphs[-1]
last_par.alignment = WD_ALIGN_PARAGRAPH.CENTER

doc.add_page_break()

# Diagnostic criteria
doc.add_heading("1. Diagnostic Criteria", level=1)
add_table(
    ["Type", "Definition", "Course"],
    [
        ["HRS-AKI (formerly Type 1)", "Rise in serum Cr \u22650.3 mg/dL in 48h, or \u226550% from baseline", "Rapidly progressive; worse short-term prognosis"],
        ["HRS-CKD (formerly Type 2)", "Reduced GFR with stable elevated creatinine", "Slowly progressive; better outcome than HRS-AKI, but still poor without transplant"],
    ]
)
doc.add_paragraph()
doc.add_paragraph(
    "Diagnosis requires: (1) cirrhosis with ascites, (2) exclusion of shock, (3) no recent "
    "nephrotoxic drug exposure, (4) no macroscopic signs of structural kidney injury "
    "(proteinuria <500 mg/day, no hematuria, normal renal ultrasound), and (5) failure of "
    "renal function to improve after diuretic withdrawal and albumin volume expansion "
    "(1 g/kg/day for 2 days)."
)

# Step-wise management
doc.add_heading("2. Step-Wise Management", level=1)

steps = [
    ("Step 1: Immediate actions", "Stop diuretics and nephrotoxic drugs (NSAIDs, aminoglycosides). Stop vasodilators. Obtain urinalysis, urine sediment, and renal ultrasound."),
    ("Step 2: Exclude other causes of AKI", "Correct volume depletion (GI bleed, over-diuresis, lactulose-induced diarrhea). Perform diagnostic paracentesis to exclude spontaneous bacterial peritonitis (SBP) and treat if present. Exclude obstruction, acute tubular necrosis, interstitial nephritis, glomerulonephritis."),
    ("Step 3: Albumin challenge", "IV albumin 1 g/kg/day (max ~100 g/day) for 48 hours. If creatinine improves, HRS is excluded - treat the identified cause. If no improvement, diagnose HRS-AKI or HRS-CKD."),
    ("Step 4: Pharmacologic therapy", "Initiate vasoconstrictor therapy with continued albumin, in an ICU or closely monitored setting (see drug table below)."),
    ("Step 5: Reassess at 48-72 hours", "Responders: continue therapy up to 14 days total, then taper. Non-responders: refractory HRS - proceed to Step 6."),
    ("Step 6: Refractory HRS", "Consider renal replacement therapy (dialysis/CRRT) as a bridge, TIPS in selected patients without contraindications (evidence limited), and expedite liver transplant evaluation."),
    ("Step 7: Definitive treatment", "Liver transplantation is the only curative therapy; renal function typically recovers. Consider combined liver-kidney transplant if renal failure has been prolonged (>4-6 weeks) or there is structural kidney damage."),
]
for i, (h, body) in enumerate(steps):
    p = doc.add_paragraph()
    run = p.add_run(h)
    run.bold = True
    run.font.color.rgb = RGBColor(0x1F, 0x4E, 0x79)
    doc.add_paragraph(body)

# Drug therapy table
doc.add_heading("3. Pharmacologic Therapy (Vasoconstrictors)", level=1)
add_table(
    ["Line", "Agent", "Typical Regimen", "Notes"],
    [
        ["1st line", "Terlipressin + Albumin", "0.5-1 mg IV bolus q4-6h or continuous infusion; titrate up to max ~12 mg/day", "Most effective agent; monitor for ischemia (cardiac, digital, mesenteric); requires close monitoring"],
        ["2nd line (if terlipressin unavailable)", "Norepinephrine + Albumin", "0.5-3 mg/hr continuous IV infusion, titrated to MAP", "Requires ICU/central line monitoring; similar efficacy to terlipressin in studies"],
        ["3rd line (used mainly in US)", "Midodrine + Octreotide + Albumin", "Midodrine 7.5-12.5 mg PO TID; Octreotide 100-200 mcg SC TID (or infusion)", "Less effective than terlipressin/norepinephrine; used when ICU-level vasoconstrictors unavailable"],
    ]
)

# Monitoring
doc.add_heading("4. Monitoring & Supportive Care", level=1)
for item in [
    "Daily serum creatinine, electrolytes, and urine output.",
    "Watch for vasoconstrictor complications: digital/mesenteric/cardiac ischemia, arrhythmias, fluid overload (pulmonary edema) from albumin.",
    "Continue treatment of precipitating factors (infection, GI bleeding).",
    "Early nephrology and hepatology/transplant consultation.",
    "Reassess transplant candidacy continuously; do not delay listing while trialing medical therapy.",
]:
    doc.add_paragraph(item, style="List Bullet")

# Prognosis
doc.add_heading("5. Prognosis", level=1)
doc.add_paragraph(
    "Prognosis is poor without liver transplantation. HRS-AKI (rapidly progressive) carries a "
    "worse short-term prognosis than HRS-CKD (stable, chronic course). Response to "
    "vasoconstrictor therapy is associated with improved survival even in the absence of "
    "immediate transplantation."
)

# References
doc.add_heading("References", level=1)
refs = [
    "Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Hepatorenal Syndrome.",
    "Goldman-Cecil Medicine, International Edition, 2-Volume Set - Hepatorenal Syndrome.",
    "Braga QM, Schacher FC, Mattos AA. Terlipressin for the treatment of hepatorenal syndrome: a meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2025. PMID: 40207491.",
    "Wan YM, Huang SQ, Wu HM. Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Front Pharmacol. 2024. PMID: 39295934.",
    "Gonzalez-Garay AG, Serralde-Zuniga AE, Velasco Hidalgo L, et al. Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome. Cochrane Database Syst Rev. 2024. PMID: 38235907.",
]
for r in refs:
    doc.add_paragraph(r, style="List Bullet")

doc.add_paragraph()
note = doc.add_paragraph()
note_run = note.add_run("This document is a clinical quick-reference summary and does not replace institutional protocols or full clinical judgment.")
note_run.italic = True
note_run.font.size = Pt(9)
note_run.font.color.rgb = RGBColor(0x77, 0x77, 0x77)

doc.save("/tmp/workspace/hrs-management/output/HRS_Management_Summary.docx")
print("DOCX saved.")

Running Command

cd /tmp/workspace/hrs-management && python3 build_docx.py && ls -la output

I've created a complete clinical decision document for HRS management. It includes a visual flowchart plus a structured written summary (diagnostic criteria, step-wise management, drug dosing table, monitoring, and prognosis) - all cited from Harrison's, Goldman-Cecil, and recent PubMed evidence.

HRS Management Summary

Word Document · DOCX

Document contents:

Decision flowchart (embedded image) - trigger → initial workup → exclude other AKI causes → albumin challenge → branch (HRS excluded vs. confirmed) → vasoconstrictor therapy → reassessment → refractory HRS options → definitive transplant.
Diagnostic criteria table - HRS-AKI vs HRS-CKD definitions and course.
Step-wise management (7 steps) - from stopping diuretics/nephrotoxins through liver transplant.
Drug therapy table - terlipressin, norepinephrine, midodrine+octreotide regimens with doses and monitoring notes.
Monitoring & supportive care checklist.
Prognosis section.
References - Harrison's 22e, Goldman-Cecil Intl Ed, plus 3 recent PubMed sources (terlipressin meta-analyses PMID 40207491 & 39295934, and Cochrane TIPS review PMID 38235907).

The standalone flowchart image is also saved separately if you just want the visual: /tmp/workspace/hrs-management/output/hrs_flowchart.png

Let me know if you'd like this reformatted as a PDF or a single-page laminated pocket card version instead.

non alcholic fatty liver disease investigation and management in short

Finding Sources

Searching PubMed

"nonalcoholic fatty liver disease" AND management

Reading File

Searching the Web

resmetirom NAFLD MASH FDA approval treatment guideline 2024

NAFLD (now MASLD) - Investigation and Management, in Short

Note: NAFLD has been renamed MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH -> MASH in current guidelines, though older terms are still widely used.

Investigation

1. Suspect it in: Patients with obesity, T2DM, metabolic syndrome, or incidental hepatic steatosis on imaging/abnormal LFTs.

2. Exclude other causes first

Alcohol use history (quantify intake)
Viral hepatitis (HBsAg, HCV Ab), autoimmune, hemochromatosis, Wilson disease, drug-induced steatosis (steroids, amiodarone, valproate, tamoxifen)

3. Confirm steatosis

Ultrasound (first-line, low cost) - bright/hyperechoic liver
CT/MRI if needed
Labs: mild-moderate transaminase elevation (ALT often > AST, unlike alcoholic disease), lipid panel, fasting glucose/HbA1c

4. Risk-stratify fibrosis (key step - determines management intensity)

Non-invasive scoring: FIB-4 index or NAFLD Fibrosis Score (NFS) as first-line triage
Elastography: Vibration-controlled transient elastography (VCTE/FibroScan) or MR elastography (MRE) for indeterminate/high-risk FIB-4
Liver biopsy: gold standard for confirming steatohepatitis (NASH/MASH) and staging fibrosis - reserved for diagnostic uncertainty or when result would change management (e.g., before pharmacotherapy)

Management

1. Lifestyle (foundation of therapy for everyone)

Weight loss: 7-10% body weight reduces liver enzymes and histologic activity; ≥10% can improve fibrosis
Diet (Mediterranean-style), regular aerobic exercise
Strict glycemic control, treat dyslipidemia
Stop hepatotoxic drugs/alcohol
Bariatric surgery or newer weight-loss agents (GLP-1 receptor agonists) if obese and lifestyle measures fail

2. Pharmacologic therapy (for biopsy-proven or high-risk MASH with significant fibrosis, F2-F3)

Resmetirom (Rezdiffra) - first FDA-approved drug (March 2024) specifically for noncirrhotic MASH with moderate-advanced fibrosis (F2-F3), a thyroid hormone receptor-beta agonist; improved MASH resolution and fibrosis in the MAESTRO-NASH trial
Semaglutide (GLP-1 agonist) - gained accelerated approval (2025) for MASH; also benefits weight and cardiometabolic risk
Pioglitazone - improves histology in biopsy-proven NASH, especially with diabetes
Vitamin E (800 IU/day) - option in non-diabetic, biopsy-proven NASH (limited by long-term safety concerns)

3. Cirrhosis/advanced fibrosis (F4)

Screen for HCC (ultrasound +/- AFP every 6 months) and esophageal varices
Manage as any cirrhosis; liver transplant evaluation if decompensated - NAFLD/MASLD is now a leading indication for transplant

4. Follow-up

Reassess fibrosis risk periodically (FIB-4/elastography)
Manage cardiovascular risk aggressively - cardiovascular disease, not liver disease, is the leading cause of death in NAFLD/MASLD

Sources: Yamada's Textbook of Gastroenterology, 7th ed.; The Washington Manual of Medical Therapeutics.

Recent evidence: A 2025 Bayesian network meta-analysis (PMID: 39963857) and 2024 network meta-analysis on lifestyle vs. pharmacologic strategies (PMID: 38509775) support pioglitazone and combined lifestyle+drug approaches. The 2023 AGA Clinical Practice Update (PMID: 37542503) endorses FIB-4 plus elastography as the non-invasive diagnostic pathway described above. These are consistent with the textbook-based summary but reflect more current drug approvals (resmetirom, semaglutide) not yet in most textbooks.

give in flowchart in short to write in exams of above mash

MASH (NAFLD/NASH) - Exam Flowchart (Short Form)

Suspected NAFLD/MASH
(Obesity, T2DM, Metabolic syndrome, incidental steatosis/deranged LFT)
        |
        v
Exclude other causes
(Alcohol, Viral hepatitis, Autoimmune, Wilson's, Hemochromatosis, Drugs)
        |
        v
Confirm steatosis
(USG / CT / MRI + LFT, Lipid profile, HbA1c)
        |
        v
Risk-stratify fibrosis
(FIB-4 / NFS score)
        |
   -----------------
   |               |
Low risk        High/Indeterminate risk
   |               |
   v               v
Routine        Elastography (FibroScan/MRE)
follow-up           |
                     v
              Still high risk / uncertain
                     |
                     v
              Liver biopsy (gold standard)
                     |
                     v
        Confirms MASH +/- fibrosis stage (F0-F4)
                     |
        -----------------------------
        |                           |
   F0-F1 (mild)              F2-F3 (significant fibrosis)      F4 (cirrhosis)
        |                           |                                |
        v                           v                                v
 Lifestyle only:            Lifestyle + Drug therapy:          Manage as cirrhosis:
 - Weight loss 7-10%        - Resmetirom (FDA approved)        - HCC surveillance (USG+AFP 6-monthly)
 - Diet + exercise          - Semaglutide (GLP-1 agonist)      - Variceal screening
 - Control DM/lipids        - Pioglitazone (esp. if diabetic)  - Transplant evaluation if decompensated
                            - Vitamin E (non-diabetic)
                     |
                     v
        Address cardiovascular risk in ALL patients
        (leading cause of death in NAFLD/MASH)

Exam tip - one-line summary per box:

Suspect → risk factors + incidental findings
Exclude → alcohol, viral, autoimmune, drugs
Confirm → imaging + LFTs
Stratify → FIB-4/NFS → elastography → biopsy if needed
Treat → lifestyle for all; add resmetirom/semaglutide/pioglitazone/vitamin E for significant fibrosis (F2-F3); cirrhosis care for F4
Always control cardiovascular risk

This is a shared conversation. Sign in to Orris to start your own chat.